Release form, composition and packing
Ointment for external use yellowish, homogenous, with a weak characteristic odor. 1 g bacitracin (in the form of bacitracin zinc) 250 IU of neomycin (in the form of sulfate) 5000 IU. Other ingredients: lanolin, white soft paraffin.
Powder for external use finely divided, from white to yellowish. 1 g bacitracin (in the form of bacitracin zinc) 250 IU of neomycin (in the form of sulfate) 5000 IU. Excipients: Basis sterilized powder (corn starch, contains less than 2% magnesium oxide).
Clinico-pharmacological group: drug with antibacterial activity for outdoor use.
Pharmacological action
Combination antibiotic for topical use. Contains two antibiotics that have bactericidal activity, neomycin and bacitracin. Bacitracin is a polypeptide antibiotic that inhibits cell wall synthesis. Neomycin is an aminoglycoside antibiotic that inhibits protein synthesis of bacteria.
Bacitracin is active against gram-positive (Streptococcus spp. / Including hemolytic streptococcus /, Staphylococcus spp.) And some Gram-negative microorganisms. Resistance to bacitracin is rare. It has good tissue tolerability, the inactivation of biological products, blood and tissue components are not marked. Neomycin is active against gram-positive and Gram-negative bacteria. Through the use of a combination of these two antibiotics achieved a wide range of drug action and synergy of action against a number of microorganisms such as staphylococci.
Pharmacokinetics
Active ingredients are generally not absorbed (even broken skin), however, present in the skin of their high concentrations. When applying the product to large areas of skin lesions should take into account the possibility of systemic absorption of the drug.
Statement
Treatment of infectious and inflammatory skin diseases caused by microorganisms susceptible to the drug:
Powder
bacterial skin infections limited distribution, including moist contagious impetigo, infected trophic ulcers of the lower limbs, infected eczema, bacterial diaper dermatitis, secondary bacterial infection of diseases caused by Herpes simplex, Varicella zoster (including varicella);
prevention of umbilical infections in newborns;
Prevention of infection after surgery (including dermatological) procedures: in the postoperative period (after the excision of tissue, cauterization, episiotomy, treatment of cracks, weeping wounds, and sutures).
Ointment
foci of infection of the skin, t.ch.furunkuly, carbuncles (after surgery), staphylococcal sycosis, a deep folliculitis, purulent hydradenitis, paronychia;
bacterial skin infections limited distribution, including contagious impetigo, infected ulcers of the lower extremities, secondary infected eczema and secondary infection with dermatosis, cuts, bruises, burns, cosmetic surgery and skin transplantation (also for prevention and to impregnate bandages);
prevention of infection after surgery (as part of combination therapy in the postoperative period).
Dosing regimen
The drug is applied thinly to the affected areas: powder - 2-4 times a day, ointment - 2-3 times / day (in order to enhance the effectiveness of possible application of the ointment under the bandage). Application of ointment with bristles, preferably at the local treatment of infected wounds and cavities (including bacterial infections of the ear canal without perforating the eardrum, wounds or surgical incisions healing by secondary intention).
With burns over 20% of body powder should be applied no more than 1 time per day, especially in the case of reduction of renal function (because it is possible absorption of the active ingredient). When applied externally dose of neomycin should not exceed 1 g / day (equivalent to 200 grams of powder or ointment) for 7 days. When you know the maximum dose - less than 100 g.
Side effect
Allergic reactions: a long-term use - redness, dry skin, skin rash, itching. Most allergic reactions are the type of contact eczema (50% of cases are associated with cross-allergy to other aminoglycosides), and rare.
Systemic effects: with extensive lesions of the skin should consider the possibility of absorption of the drug and the development of mapping and nephrotoxic effects and disorders of neuromuscular conduction.
When applied topically Baneotsin generally well tolerated.
Contraindications
marked impairment of renal function (due to cardiac or renal failure);
disease kohleo-vestibular system;
extensive skin lesions (risk of Valium effect it if systemic absorption);
diseases of the eye (for application of powder);
Hypersensitivity to bacitracin, neomycin, or to other aminoglycosides.
Pregnancy and lactation
Use of the drug Baneotsin during pregnancy and lactation is possible only if the intended benefits to the mother outweighs the potential risk to the fetus or infant.
Use in hepatic dysfunction
Because the risk of toxic effects increases with a decrease in liver function in patients with liver failure should be blood and urine tests, together with audiometric studies before and during therapy with Baneotsin.
Use in renal impairment
When used in doses far exceeding the recommended, due to possible absorption should pay attention to symptoms suggestive of nephro-or ototoxic reactions. Because the risk of toxic effects increases with a decrease in renal function in patients with renal failure should be blood and urine tests, together with audiometric studies before and during therapy with Baneotsin.
Cautions
Avoid getting product into eyes. When used in doses far exceeding the recommended, due to possible absorption should pay attention to symptoms suggestive of nephro-or ototoxic reactions.
Because the risk of toxic effects increases with a decrease in liver function and / or renal function in patients with hepatic and / or renal failure should be blood and urine tests, together with audiometric studies before and during therapy with Baneotsin.
With the possible removal (extensive violation of the integrity of the skin), it is necessary to monitor the possible emergence of signs of neuromuscular blockade, especially in patients with acidosis, myasthenia gravis (myasthenia gravis) or other neuromuscular diseases.
With the development of neuromuscular blockade shows calcium supplements or neostigmine. With prolonged use of the drug should be monitored closely for excessive growth of resistant organisms.
If necessary, appropriate treatment. In the case of the drug in children, patients with impaired liver function and kidney, as well as a large work surface area, prolonged use, and deep skin lesions should consult a physician. With the development of allergic reactions and superinfection with the drug should be discontinued.
Overdose
Currently, cases of drug overdose Baneotsin were reported.
Drug Interactions
If there is systemic absorption, then the simultaneous prescription of antibiotics or cephalosporins, aminoglycosides increases the risk of nephrotoxic reactions. While the application Baneotsina with ethacrynic acid or furosemide increases the risk of mapping and nephrotoxic reactions.
In the case of systemic absorption, while the application Baneotsina with opioid analgesics, anesthetics and muscle relaxants increases the risk of neuromuscular blockade. There were no cases of incompatibility, bacitracin and neomycin.
Conditions and terms of
The drug should be stored in a place inaccessible to children at a temperature below 25 ° C. The drug in powder form should be kept in the dark and dry place. Shelf life - 3 years.
Ointment for external use yellowish, homogenous, with a weak characteristic odor. 1 g bacitracin (in the form of bacitracin zinc) 250 IU of neomycin (in the form of sulfate) 5000 IU. Other ingredients: lanolin, white soft paraffin.
Powder for external use finely divided, from white to yellowish. 1 g bacitracin (in the form of bacitracin zinc) 250 IU of neomycin (in the form of sulfate) 5000 IU. Excipients: Basis sterilized powder (corn starch, contains less than 2% magnesium oxide).
Clinico-pharmacological group: drug with antibacterial activity for outdoor use.
Pharmacological action
Combination antibiotic for topical use. Contains two antibiotics that have bactericidal activity, neomycin and bacitracin. Bacitracin is a polypeptide antibiotic that inhibits cell wall synthesis. Neomycin is an aminoglycoside antibiotic that inhibits protein synthesis of bacteria.
Bacitracin is active against gram-positive (Streptococcus spp. / Including hemolytic streptococcus /, Staphylococcus spp.) And some Gram-negative microorganisms. Resistance to bacitracin is rare. It has good tissue tolerability, the inactivation of biological products, blood and tissue components are not marked. Neomycin is active against gram-positive and Gram-negative bacteria. Through the use of a combination of these two antibiotics achieved a wide range of drug action and synergy of action against a number of microorganisms such as staphylococci.
Pharmacokinetics
Active ingredients are generally not absorbed (even broken skin), however, present in the skin of their high concentrations. When applying the product to large areas of skin lesions should take into account the possibility of systemic absorption of the drug.
Statement
Treatment of infectious and inflammatory skin diseases caused by microorganisms susceptible to the drug:
Powder
bacterial skin infections limited distribution, including moist contagious impetigo, infected trophic ulcers of the lower limbs, infected eczema, bacterial diaper dermatitis, secondary bacterial infection of diseases caused by Herpes simplex, Varicella zoster (including varicella);
prevention of umbilical infections in newborns;
Prevention of infection after surgery (including dermatological) procedures: in the postoperative period (after the excision of tissue, cauterization, episiotomy, treatment of cracks, weeping wounds, and sutures).
Ointment
foci of infection of the skin, t.ch.furunkuly, carbuncles (after surgery), staphylococcal sycosis, a deep folliculitis, purulent hydradenitis, paronychia;
bacterial skin infections limited distribution, including contagious impetigo, infected ulcers of the lower extremities, secondary infected eczema and secondary infection with dermatosis, cuts, bruises, burns, cosmetic surgery and skin transplantation (also for prevention and to impregnate bandages);
prevention of infection after surgery (as part of combination therapy in the postoperative period).
Dosing regimen
The drug is applied thinly to the affected areas: powder - 2-4 times a day, ointment - 2-3 times / day (in order to enhance the effectiveness of possible application of the ointment under the bandage). Application of ointment with bristles, preferably at the local treatment of infected wounds and cavities (including bacterial infections of the ear canal without perforating the eardrum, wounds or surgical incisions healing by secondary intention).
With burns over 20% of body powder should be applied no more than 1 time per day, especially in the case of reduction of renal function (because it is possible absorption of the active ingredient). When applied externally dose of neomycin should not exceed 1 g / day (equivalent to 200 grams of powder or ointment) for 7 days. When you know the maximum dose - less than 100 g.
Side effect
Allergic reactions: a long-term use - redness, dry skin, skin rash, itching. Most allergic reactions are the type of contact eczema (50% of cases are associated with cross-allergy to other aminoglycosides), and rare.
Systemic effects: with extensive lesions of the skin should consider the possibility of absorption of the drug and the development of mapping and nephrotoxic effects and disorders of neuromuscular conduction.
When applied topically Baneotsin generally well tolerated.
Contraindications
marked impairment of renal function (due to cardiac or renal failure);
disease kohleo-vestibular system;
extensive skin lesions (risk of Valium effect it if systemic absorption);
diseases of the eye (for application of powder);
Hypersensitivity to bacitracin, neomycin, or to other aminoglycosides.
Pregnancy and lactation
Use of the drug Baneotsin during pregnancy and lactation is possible only if the intended benefits to the mother outweighs the potential risk to the fetus or infant.
Use in hepatic dysfunction
Because the risk of toxic effects increases with a decrease in liver function in patients with liver failure should be blood and urine tests, together with audiometric studies before and during therapy with Baneotsin.
Use in renal impairment
When used in doses far exceeding the recommended, due to possible absorption should pay attention to symptoms suggestive of nephro-or ototoxic reactions. Because the risk of toxic effects increases with a decrease in renal function in patients with renal failure should be blood and urine tests, together with audiometric studies before and during therapy with Baneotsin.
Cautions
Avoid getting product into eyes. When used in doses far exceeding the recommended, due to possible absorption should pay attention to symptoms suggestive of nephro-or ototoxic reactions.
Because the risk of toxic effects increases with a decrease in liver function and / or renal function in patients with hepatic and / or renal failure should be blood and urine tests, together with audiometric studies before and during therapy with Baneotsin.
With the possible removal (extensive violation of the integrity of the skin), it is necessary to monitor the possible emergence of signs of neuromuscular blockade, especially in patients with acidosis, myasthenia gravis (myasthenia gravis) or other neuromuscular diseases.
With the development of neuromuscular blockade shows calcium supplements or neostigmine. With prolonged use of the drug should be monitored closely for excessive growth of resistant organisms.
If necessary, appropriate treatment. In the case of the drug in children, patients with impaired liver function and kidney, as well as a large work surface area, prolonged use, and deep skin lesions should consult a physician. With the development of allergic reactions and superinfection with the drug should be discontinued.
Overdose
Currently, cases of drug overdose Baneotsin were reported.
Drug Interactions
If there is systemic absorption, then the simultaneous prescription of antibiotics or cephalosporins, aminoglycosides increases the risk of nephrotoxic reactions. While the application Baneotsina with ethacrynic acid or furosemide increases the risk of mapping and nephrotoxic reactions.
In the case of systemic absorption, while the application Baneotsina with opioid analgesics, anesthetics and muscle relaxants increases the risk of neuromuscular blockade. There were no cases of incompatibility, bacitracin and neomycin.
Conditions and terms of
The drug should be stored in a place inaccessible to children at a temperature below 25 ° C. The drug in powder form should be kept in the dark and dry place. Shelf life - 3 years.
No comments:
Post a Comment